


**Figure 1: Rituximab Crystals**



10034950, 122601  
T0927, 0564E001

**Figure 2: Infliximab Crystals**



10034950, 122601

**Figure 3: Rituximab Cube-shaped Crystals**




**Figure 4: Rituximab Small Needle-like Crystals**




10034930, 122601

**Figure 5: Trastuzumab Crystals**




10034950 122601


**Figure 6: Trastuzumab Long Needle-like Crystals**



**Figure 7: Infliximab Star-shaped Crystals**




**Figure 8: Crystallized Rituximab-Induced Direct Cytotoxicity**







**Figure 9: Crystallized Rituximab-Induced Complement-Dependent Cytotoxicity**



**Figure 10: Analysis of Dissolved Rituximab Crystals**



**Figure 11: Analysis of Dissolved Trastuzumab Crystals**



[illegible]

Figure 13: Crystalline Trastuzumab after treatment with Acetone





Figure 14: Soluble Trastuzumab after treatment with Acetone



**Figure 15: Bioavailability of Crystalline Trastuzumab Administered Intravenously (I.V.) or Subcutaneously (S.C.)**

